Document is current
Any future updates will be listed below
-
Authors
Kondo, Fumiaki
Sugihara, Takahiko https://orcid.org/0000-0002-7181-7494
Umezawa, Natsuka
Hasegawa, Hisanori
Hosoya, Tadashi
Kimura, Naoki
Mori, Masaaki
Yasuda, Shinsuke
-
Funding
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (20FC1050)
- License Information
-
More Information
Article History
Received: 21 October 2021
Accepted: 19 April 2022
First Online: 29 April 2022
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Epidemiological Research in Japan. The study was approved by the Ethics Committee of Tokyo Medical and Dental University (M2019-301).
: Not applicable.
: Tokyo Medical and Dental University received unrestricted research grants for the salary of the members in Department of Lifetime Clinical Immunology from Abbvie Japan; Asahi-Kasei; Ayumi Pharmaceutical Corporation; Chugai Pharmaceutical Co., Ltd.; CSL Behring K.K.; Japan Blood Products Organization; Nippon Kayaku; and UCB Japan Co. Ltd. TS has received research grants from AsahiKASEI Co., Ltd.; Daiichi Sankyo.; and Ono Pharmaceutical. TS has received honoraria from Abbvie Japan Co., Ltd.; AsahiKASEI Co., Ltd.; Astellas Pharma Inc.; Ayumi Pharmaceutical; Bristol Myers Squibb K.K.; Chugai Pharmaceutical Co., Ltd.; Eli Lilly Japan K.K.; Mitsubishi-Tanabe Pharma Co.; Ono Pharmaceutical; Pfizer Japan Inc.; Takeda Pharmaceutical Co. Ltd.; and UCB Japan Co. Ltd. NK has received research grants from Chugai Pharmaceutical Co., Ltd.; UCB Japan Co., Ltd; CSL Behring K.K.; Ayumi Pharmaceutical; Japan Blood Products Organization; and Novartis Pharma K.K. NK has received honoraria from Eisai Co., Ltd.; AbbVie GK; Asahi KASEI Pharma Co.; Novartis Pharma K.K.; Japan Blood Products Organization; Kissei Pharmaceutical Co.LTD.; Ono Pharmaceutical; and Mitsubishi-Tanabe Pharma Co. NK has received medical writing fees from AbbVie GK, Asahi Kasei Pharma Co, and Chugai Pharmaceutical Co., LTD. SY received grants and personal fees from Abbvie, Asahi Kasei, Chugai Pharmaceutical, Ono pharmaceuticals, Eisai, and Tanabe-Mitsubishi Pharmaceutical and personal fees from Eli Lilly, GlaxoSmithKline, and Pfizer. All other authors have declared no competing interests.
